OOIR: Observatory of International Research

Papers

(The H4-Index of Biomarker Research is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study	185
Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion	171
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	164
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	143
Unraveling the immune microenvironment in primary CNS lymphoma	133
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	124
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	118
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting	117
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	117
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	114
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	108
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	103
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	101
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	99
Mitochondrial transfer in hematological malignancies	96
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	94
The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	93
The molecular landscape of the C1498 murine acute myeloid leukemia cell line	92
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	92
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	92
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	91
Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis	91
Emerging roles of circular RNAs and enhancer RNAs: new insights into the development and management of neurodegenerative disorders	90
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	82
The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease	82

Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation	80
miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC	79
Unveiling the potential of CLL-1: a promising target for AML therapy	79
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	75
Circadian rhythm-guided cellular therapy in hematologic malignancies: mechanisms, clinical evidence, and optimization strategies	74
The formation and function of tertiary lymphoid structures	71
INHBA–S100A16 dysregulation enables a non-invasive molecular stratification platform for rapid detection of oral squamous cell carcinoma: results from a large diagnostic case-control study	67
tRNA modifications in cancer: from molecular mechanisms to clinical translation	67
p53 biology and reactivation for improved therapy in MDS and AML	63
The circadian architecture of tumor immunity: mechanistic insights and treatment strategies	63
Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	62
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	62
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	60
Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	57
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	57
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	57
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	57
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	56
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	55
Proteomic and histopathologic profiling reveal molecular features and clinical biomarkers of coronary atherosclerosis	55
Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions	54
The role and metabolic adaptations of neutrophils in premetastatic niches	54
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	53
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	53
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	52
The role of BATF in immune cell differentiation and autoimmune diseases	52
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	51